SG11202100928QA - Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy - Google Patents
Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophyInfo
- Publication number
- SG11202100928QA SG11202100928QA SG11202100928QA SG11202100928QA SG11202100928QA SG 11202100928Q A SG11202100928Q A SG 11202100928QA SG 11202100928Q A SG11202100928Q A SG 11202100928QA SG 11202100928Q A SG11202100928Q A SG 11202100928QA SG 11202100928Q A SG11202100928Q A SG 11202100928QA
- Authority
- SG
- Singapore
- Prior art keywords
- muscular dystrophy
- facioscapulohumeral muscular
- muscle targeting
- targeting complexes
- treating facioscapulohumeral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02008—Hypoxanthine phosphoribosyltransferase (2.4.2.8)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/314—Phosphoramidates
- C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3233—Morpholino-type ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862713933P | 2018-08-02 | 2018-08-02 | |
PCT/US2019/044990 WO2020028864A1 (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202100928QA true SG11202100928QA (en) | 2021-02-25 |
Family
ID=69232303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202100928QA SG11202100928QA (en) | 2018-08-02 | 2019-08-02 | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
Country Status (12)
Country | Link |
---|---|
US (9) | US20220193250A1 (ja) |
EP (1) | EP3830259A4 (ja) |
JP (1) | JP2021533200A (ja) |
KR (1) | KR20210081324A (ja) |
CN (1) | CN112912499A (ja) |
AU (1) | AU2019316103A1 (ja) |
CA (1) | CA3108289A1 (ja) |
EA (1) | EA202190416A1 (ja) |
IL (1) | IL280426A (ja) |
MX (1) | MX2021001284A (ja) |
SG (1) | SG11202100928QA (ja) |
WO (1) | WO2020028864A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
TW202043468A (zh) * | 2019-01-22 | 2020-12-01 | 美商科羅生物公司 | Rna編輯之寡核苷酸及其用途 |
EP3914261A4 (en) | 2019-01-22 | 2023-06-28 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
CA3172111A1 (en) * | 2020-03-19 | 2021-09-23 | Barbora MALECOVA | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
EP4127175A2 (en) | 2020-04-02 | 2023-02-08 | Mirecule, Inc. | Targeted inhibition using engineered oligonucleotides |
UY39417A (es) | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
KR20230128314A (ko) * | 2020-12-31 | 2023-09-04 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을치료하기 위한 그의 용도 |
WO2022271549A1 (en) * | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
WO2023283629A1 (en) * | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
WO2023006985A1 (en) * | 2021-07-30 | 2023-02-02 | 4Basebio Uk Ltd | Nanoparticles and peptides for the delivery of cargos to muscle cells |
EP4124345A1 (en) * | 2021-07-30 | 2023-02-01 | 4basebio UK Ltd | Nanoparticles for muscle delivery |
TW202328187A (zh) | 2021-09-01 | 2023-07-16 | 美商百健Ma公司 | 抗運鐵蛋白受體抗體及其用途 |
CA3231330A1 (en) * | 2021-09-16 | 2023-03-23 | Avidity Biosciences, Inc. | Compositions and methods of treating facioscapulohumeral muscular dystrophy |
IL312170A (en) * | 2021-11-12 | 2024-06-01 | Dyne Therapeutics Inc | Muscle targeting complexes for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
WO2024102965A1 (en) * | 2022-11-10 | 2024-05-16 | Ohio State Innovation Foundation | Designer extracellular vesicles for targeted delivery to muscle cells |
Family Cites Families (251)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2631173A (en) | 1949-01-04 | 1953-03-10 | Phillips Petroleum Co | Production of cyclooctadiene |
IL54795A (en) | 1978-05-26 | 1980-10-26 | Yeda Res & Dev | Analgesic compositions comprising substituted bicyclic and spiroaliphatic amines and certain novel compounds of these types |
ATE108692T1 (de) | 1988-03-02 | 1994-08-15 | Uab Research Foundation | Reversibel mechanisch-chemisch arbeitende maschinen, die aus bioelastomeren bestehen, die zu regelbaren inversen temperaturübergängen fähig sind, zur umwandlung von chemischer in mechanische arbeit. |
WO1991004753A1 (en) | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US6255455B1 (en) | 1996-10-11 | 2001-07-03 | The Trustees Of The University Of Pennsylvania | Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof |
ES2236178T3 (es) | 2000-02-22 | 2005-07-16 | Banyu Pharmaceutical Co., Ltd. | Nuevos compuestos de imidazolina. |
US6784291B2 (en) | 2000-05-04 | 2004-08-31 | Avi Biopharma, Inc. | Splice-region antisense composition and method |
EP1191097A1 (en) | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
US20040063654A1 (en) | 2001-11-02 | 2004-04-01 | Davis Mark E. | Methods and compositions for therapeutic use of RNA interference |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
AU2003225724A1 (en) | 2002-03-11 | 2003-09-29 | Momenta Pharmaceuticals, Inc. | Analysis of sulfated polysaccharides |
JP2006507841A (ja) | 2002-11-14 | 2006-03-09 | ダーマコン, インコーポレイテッド | 機能的siRNAおよび超機能的siRNA |
DK2284269T3 (en) | 2002-11-18 | 2017-10-23 | Roche Innovation Ct Copenhagen As | Antisense design |
CA2796924C (en) | 2002-11-25 | 2016-12-13 | Nonprofit Organization Translational Research Organization Of Duchenne Muscular Dystrophy | Ena nucleic acid pharmaceuticals capable of modifying splicing of mrna precursors |
WO2004058717A1 (en) | 2002-12-20 | 2004-07-15 | X-Ceptor Therapeutics, Inc. | Isoquinolinone derivatives and their use as therapeutic agents |
DK1592793T3 (da) | 2003-02-10 | 2009-10-26 | Santaris Pharma As | Oligomeriske forbindelser for modulation af Survivin ekspression |
AU2003225410A1 (en) | 2003-03-21 | 2004-10-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
US7592143B2 (en) | 2003-04-18 | 2009-09-22 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
WO2005087217A1 (en) | 2004-03-05 | 2005-09-22 | The General Hospital Corporation | Compositions and methods for modulating interaction between polypeptides |
US20080199960A1 (en) | 2004-05-13 | 2008-08-21 | Juliano Rudolph L | Methods for the Delivery of Oligomeric Compounds |
IL179285A (en) | 2004-05-14 | 2011-04-28 | Rosetta Genomics Ltd | Micrornas and uses thereof |
SI1766010T1 (sl) | 2004-06-28 | 2011-06-30 | Univ Western Australia | Protismiselni oligonukleotidi za induciranje preskakovanja eksonov in postopki za njihovo uporabo |
WO2006022688A1 (en) | 2004-08-06 | 2006-03-02 | Applera Corporation | Diagnosis of pancreatic cancer by using pancreatic targets |
FR2874384B1 (fr) | 2004-08-17 | 2010-07-30 | Genethon | Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables |
US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
US20120122801A1 (en) | 2005-01-05 | 2012-05-17 | Prosensa B.V. | Mannose-6-phosphate receptor mediated gene transfer into muscle cells |
WO2006091796A2 (en) | 2005-02-22 | 2006-08-31 | Acucela, Inc. | Compositions and methods for diagnosing and treating retinal diseases |
EP1940861A4 (en) | 2005-10-06 | 2009-09-09 | Univ Delaware | G-rich polynucleotide for the treatment of chorea huntingtone |
JP2007104971A (ja) | 2005-10-14 | 2007-04-26 | New Industry Research Organization | ミオスタチンのスプライシング制御アンチセンスオリゴヌクレオチド |
WO2007089612A2 (en) | 2006-01-30 | 2007-08-09 | President And Fellows Of Harvard College | Methods and compositions for treating and preventing bacterial infections |
EP3438131B1 (en) | 2006-02-10 | 2022-03-16 | Life Technologies Corporation | Oligosaccharide modification and labeling of proteins |
US8859752B2 (en) | 2006-04-18 | 2014-10-14 | The Trustees Of The University Of Pennsylvania | SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP) |
CN103554205A (zh) | 2006-05-05 | 2014-02-05 | Isis制药公司 | 调节gccr的表达的化合物和方法 |
EP1857548A1 (en) | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
PT2049664E (pt) | 2006-08-11 | 2012-01-03 | Prosensa Technologies Bv | Oligonucleotídeos de cadeia simples complementares dos elementos repetitivos para tratar perturbações genéticas associadas à instabilidade das repetições do adn |
DK2410054T4 (da) | 2006-10-18 | 2020-02-10 | Ionis Pharmaceuticals Inc | Antisenseforbindelser |
ES2569365T3 (es) | 2006-11-29 | 2016-05-10 | Nationwide Children's Hospital | Inhibición de miostatina para la potenciación de músculo y/o la mejora de la función muscular |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
EP2149605B1 (en) | 2007-03-22 | 2013-07-03 | Santaris Pharma A/S | Short RNA antagonist compounds for the modulation of target mRNA |
CA2704049A1 (en) | 2007-10-26 | 2009-04-30 | Academisch Ziekenhuis Leiden | Means and methods for counteracting muscle disorders |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
EP2274423A2 (en) | 2008-04-04 | 2011-01-19 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
WO2009144481A2 (en) | 2008-05-30 | 2009-12-03 | Isis Innovation Limited | Conjugates for delivery of biologically active compounds |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
CA3066050A1 (en) | 2008-10-24 | 2010-04-29 | Sarepta Therapeutics, Inc. | Multiple exon skipping compositions for dmd |
PT2607484E (pt) | 2008-10-27 | 2016-03-09 | Academisch Ziekenhuis Leiden | Métodos e meios para o salto eficiente do exão 45 no pré-mrna de distrofia muscular de duchenne |
AU2010239779A1 (en) | 2009-04-24 | 2011-11-17 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating DMD |
US9012139B2 (en) * | 2009-05-08 | 2015-04-21 | Curna, Inc. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to DMD family |
FR2947269B1 (fr) | 2009-06-29 | 2013-01-18 | Sanofi Aventis | Nouveaux composes anticancereux |
WO2011036640A2 (en) | 2009-09-24 | 2011-03-31 | Cellectis | Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations |
PL2499249T3 (pl) | 2009-11-12 | 2019-03-29 | Univ Western Australia | Cząsteczki antysensowne i sposoby leczenia patologii |
WO2011078797A2 (en) | 2009-12-22 | 2011-06-30 | Singapore Health Services Pte. Ltd | Antisense oligonucleotides and uses threreof |
WO2011130164A2 (en) | 2010-04-13 | 2011-10-20 | The Regents Of The University Of California | Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer |
BR112012026213B1 (pt) | 2010-04-15 | 2021-12-28 | Medimmune Limited | Compostos de pirrolobenzodiazepinas, conjugado das mesmas, composição farmacêutica compreendendo o conjugado e uso do mesmo para o tratamento de uma doença proliferativa |
JP5920936B2 (ja) | 2010-04-27 | 2016-05-18 | シンアフィックス ビー.ブイ. | 縮合シクロオクチン化合物及び無金属クリック反応におけるそれらの使用 |
WO2011150408A2 (en) | 2010-05-28 | 2011-12-01 | Avi Biopharma, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
IT1400425B1 (it) | 2010-06-08 | 2013-05-31 | Amsterdam Molecular Therapeutics Bv | Modified snrnas for use in therapy. |
RU2012157167A (ru) | 2010-07-12 | 2014-08-20 | КовЭкс Текнолоджиз Айэлэнд Лимитед | Полифункциональные антительные конъюгаты |
CN106434648A (zh) | 2010-07-19 | 2017-02-22 | F·C·贝内特 | 肌强直性营养障碍蛋白激酶(dmpk)表达的调节 |
US10865445B2 (en) | 2010-08-18 | 2020-12-15 | Fred Hutchinson Cancer Research Center | Methods for alleviating facioscapulohumeral dystrophy (FSHD) by N siRNA molecule inhibiting the expression of DUX4-FL |
TWI541024B (zh) | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
EP3118316A1 (en) | 2010-09-02 | 2017-01-18 | Université de Mons | Agents useful in treating facioscapulohumeral muscular dystrophy |
TWI689314B (zh) | 2010-11-30 | 2020-04-01 | 建南德克公司 | 低親和力血腦障壁受體抗體及其用途 |
US10017764B2 (en) | 2011-02-08 | 2018-07-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US9078911B2 (en) | 2011-02-08 | 2015-07-14 | The Charlotte-Mecklenburg Hospital Authority | Antisense oligonucleotides |
CN107267517A (zh) | 2011-04-22 | 2017-10-20 | 比奥马林技术公司 | 用于治疗、延缓和/或预防人类遗传性疾病如强直性肌营养不良症1型的新化合物 |
JP2014523884A (ja) | 2011-06-24 | 2014-09-18 | セントローズ, エルエルシー | 細胞外標的化薬物複合体 |
WO2013016352A1 (en) * | 2011-07-25 | 2013-01-31 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
CA2843636A1 (en) | 2011-07-29 | 2013-02-07 | Fred Hutchinson Cancer Research Center | Methods and compositions for modulating the innate immune response and/or myogenesis in a mammalian subject |
US20130066063A1 (en) | 2011-09-09 | 2013-03-14 | John Cooke Hodges | Bicyclo[6.1.0]non-4-yne regents for chemical modification of oligonucleotides |
WO2013085550A2 (en) | 2011-12-05 | 2013-06-13 | Duke University | V1v2 immunogens |
EP2788087A4 (en) | 2011-12-06 | 2015-08-26 | Ohio State Innovation Foundation | NON-IONIC LOW OSMOLARITY CONTRAST AGENTS FOR THE ADMINISTRATION OF ANTISENSE OLIGONUCLEOTIDES AND THE TREATMENT OF DISEASE |
RU2619184C2 (ru) | 2011-12-28 | 2017-05-12 | Ниппон Синяку Ко., Лтд. | Антисмысловые нуклеиновые кислоты |
AU2013203422A1 (en) | 2012-01-06 | 2013-07-18 | Bioalliance C.V. | Anti-transferrin receptor antibodies and methods using same |
WO2013120038A2 (en) | 2012-02-10 | 2013-08-15 | Regents Of The University Of Minnesota | Morpholino targeting dux4 for treating fshd |
RU2014138474A (ru) | 2012-02-24 | 2016-04-10 | СтемСентРкс, Инк. | Новые модуляторы и способы применения |
US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
SI2841578T1 (sl) | 2012-04-23 | 2017-12-29 | Biomarin Technologies B.V. | Rna modulirajoči oligonukleotidi z izboljšanimi karakteristikami za zdravljenje nevromuskularnih motenj |
CA2877644A1 (en) | 2012-07-03 | 2014-01-09 | Prosensa Technologies B.V. | Oligonucleotide for the treatment of muscular dystrophy patients |
EP2684892A1 (en) | 2012-07-13 | 2014-01-15 | Association Française contre les Myopathies | Compositions and methods for duchenne muscular dystrophy gene therapy |
WO2014059353A2 (en) | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleosides and uses thereof |
RS64329B1 (sr) | 2012-10-23 | 2023-08-31 | Synaffix Bv | Modifikovano antitelo, konjugat antitela i postupak za njihovo pripremanje |
AU2012395148B2 (en) | 2012-11-24 | 2016-10-27 | Hangzhou Dac Biotech Co., Ltd. | Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules |
PT2970964T (pt) | 2013-03-14 | 2019-03-14 | Sarepta Therapeutics Inc | Composições de skipping de exões para o tratamento da distrofia muscular |
EP3662912A1 (en) | 2013-03-15 | 2020-06-10 | Sarepta Therapeutics, Inc. | Improved dosages of eteplirsen for treating duchenne muscular dystrophy |
TWI573805B (zh) | 2013-05-20 | 2017-03-11 | 建南德克公司 | 抗轉鐵蛋白受體抗體及其使用方法 |
US20160107999A1 (en) | 2013-05-24 | 2016-04-21 | Synaffix B.V. | Substituted azadibenzocyclooctyne compounds and their use in metal-free click reactions |
KR20230136697A (ko) | 2013-06-05 | 2023-09-26 | 듀크 유니버시티 | Rna-가이드 유전자 편집 및 유전자 조절 |
TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
WO2015023939A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Compositions and methods for modulating expression of frataxin |
EP3033114A4 (en) | 2013-08-16 | 2017-04-05 | Rana Therapeutics Inc. | Heterochromatin forming non-coding rnas |
JP2016531914A (ja) | 2013-08-28 | 2016-10-13 | ステムセントリックス, インコーポレイテッド | 操作された抗dll3コンジュゲートおよび使用方法 |
CA2925242A1 (en) | 2013-09-23 | 2015-03-26 | President And Fellows Of Harvard College | Allele-specific rna silencing for the treatment of hypertrophic cardiomyopathy |
WO2015057064A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Modified glycoprotein, protein-conjugate and process for the preparation thereof |
WO2015057065A1 (en) | 2013-10-14 | 2015-04-23 | Synaffix B.V. | Glycoengineered antibody, antibody-conjugate and methods for their preparation |
EP2862928A1 (en) | 2013-10-18 | 2015-04-22 | Université de Strasbourg | Dynamin 2 inhibitor for the treatment of centronuclear myopathies |
JP6672156B2 (ja) | 2013-11-11 | 2020-03-25 | サーナ・セラピューティクス・インコーポレイテッドSirna Therapeutics,Inc. | 親油性部分にコンジュゲートされたミオスタチン低分子干渉核酸(siNA)の全身性送達 |
US10344284B2 (en) | 2013-11-14 | 2019-07-09 | Lina A. Shehadeh | Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells |
EP3097080A1 (en) | 2014-01-24 | 2016-11-30 | SynAffix B.V. | Process for the cycloaddition of a halogenated 1,3-dipole compound with a (hetero)cycloalkyne |
CN106660967A (zh) | 2014-01-24 | 2017-05-10 | 西纳福克斯股份有限公司 | (杂)芳基1,3‑偶极化合物与(杂)环炔的环加成方法 |
PL3118311T3 (pl) | 2014-03-12 | 2019-09-30 | Nippon Shinyaku Co., Ltd. | Antysensowny kwas nukleinowy |
EP3119909B1 (en) | 2014-03-18 | 2019-11-13 | Fred Hutchinson Cancer Research Center | Dux4-induced gene expression in facioscapulohumeral muscular dystrophy (fshd) |
JP6750148B2 (ja) | 2014-04-25 | 2020-09-02 | 公益財団法人野口研究所 | 糖鎖切断抗体の製造方法及び均一糖鎖抗体 |
WO2015179741A1 (en) | 2014-05-23 | 2015-11-26 | Genzyme Corporation | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
CN106661577B (zh) | 2014-06-17 | 2020-05-12 | 日本新药株式会社 | 反义核酸 |
EP3177633B1 (en) | 2014-08-04 | 2022-07-20 | SynAffix B.V. | Process for the modification of a glycoprotein using a beta-(1,4)-n-acetylgalactosaminyltransferase or a mutant thereof |
AU2015301221B2 (en) | 2014-08-04 | 2020-07-02 | MiRagen Therapeutics, Inc. | Inhibitors of MYH7B and uses thereof |
US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
ES2740907T3 (es) | 2014-10-03 | 2020-02-07 | Synaffix Bv | Enlazador de sulfamida, conjugados de los mismos y métodos de preparación |
EP3218411B1 (en) | 2014-11-14 | 2022-01-12 | Ossianix, Inc. | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use |
EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
CN108064173B (zh) | 2014-11-21 | 2021-05-18 | 默沙东公司 | 胰岛素受体部分激动剂 |
US20190002876A1 (en) | 2014-12-09 | 2019-01-03 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treatment of friedreich's ataxia |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
WO2016138534A2 (en) | 2015-02-27 | 2016-09-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
ES2659816T3 (es) | 2015-04-23 | 2018-03-19 | Synaffix B.V. | Proceso para la modificación de una glucoproteína utilizando una glucosiltransferasa que es o que deriva de una (1,4)-n-acetilgalactosaminiltransferasa |
PL3292149T3 (pl) | 2015-05-04 | 2022-03-21 | Cytomx Therapeutics, Inc. | Aktywowalne przeciwciała anty-cd71 i sposoby ich stosowania |
JP6954843B2 (ja) | 2015-05-19 | 2021-10-27 | サレプタ セラピューティクス,インコーポレイテッド | ペプチドオリゴヌクレオチドコンジュゲート |
JP6858185B2 (ja) | 2015-07-22 | 2021-04-14 | イナサリス | 増殖性および炎症性疾患の処置における抗TfR抗体およびその使用 |
KR102473431B1 (ko) | 2015-09-15 | 2022-12-01 | 니뽄 신야쿠 가부시키가이샤 | 안티센스 핵산 |
CA2999192A1 (en) | 2015-09-21 | 2017-03-30 | Association Institut De Myologie | Antisense oligonucleotides hybridizing with a key element of the polyadenylation region of a dux4 pre-mrna and uses thereof |
US20180265859A1 (en) | 2015-09-23 | 2018-09-20 | UNIVERSITé LAVAL | Modification of the dystrophin gene and uses thereof |
WO2017062835A2 (en) | 2015-10-09 | 2017-04-13 | Sarepta Therapeutics, Inc. | Compositions and methods for treating duchenne muscular dystrophy and related disorders |
EP3359523A4 (en) | 2015-10-09 | 2019-07-24 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
RU2743792C2 (ru) | 2015-11-05 | 2021-02-26 | Бамбу Терапьютикс, Инк. | Модифицированные гены атаксии фридрейха и векторы для генной терапии |
HUE052155T2 (hu) | 2015-12-08 | 2021-04-28 | Regeneron Pharma | Enzimek internalizálására szolgáló készítmények és módszerek |
FR3044926B1 (fr) | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
UA124622C2 (uk) | 2015-12-18 | 2021-10-20 | ЕЙСАЙ Ар ЕНД Ді МЕНЕДЖМЕНТ КО., ЛТД. | Кон'юговані імуноглобуліни з c-кінцевим лізином |
EP3413922A1 (en) | 2016-02-08 | 2018-12-19 | SynAffix B.V. | Improved sulfamide linkers for use in bioconjugates |
IL260983B (en) | 2016-02-19 | 2022-07-01 | Genisphere Llc | Nucleic acid carriers and methods of medical use |
MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
FR3049951A1 (fr) | 2016-04-12 | 2017-10-13 | Univ Rabelais Francois | Nouvelles constructions peptidiques et leur utilisation dans le traitement de la toxoplasmose |
EA201892366A1 (ru) | 2016-04-18 | 2019-03-29 | Сарепта Терапьютикс, Инк. | Антисмысловые олигомеры и способы их применения для лечения заболеваний, связанных с геном кислой альфа-глюкозидазы |
MA45290A (fr) | 2016-05-04 | 2019-03-13 | Wave Life Sciences Ltd | Procédés et compositions d'agents biologiquement actifs |
US10953076B2 (en) | 2016-05-24 | 2021-03-23 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and GLP-1 analogues |
JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | オリゴヌクレオチド、その組成物および方法 |
EP4212176A1 (en) | 2016-06-20 | 2023-07-19 | Genahead Bio, Inc. | Antibody-drug conjugate |
US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
KR20190027373A (ko) | 2016-07-05 | 2019-03-14 | 바이오마린 테크놀로지스 비.브이. | 유전적 장애 치료를 위한, 특징이 개선된, 비사이클릭 스캐폴드 모이어티를 포함하는 프리-mrna 스플라이스 스위칭 또는 조정 올리고뉴클레오티드 |
US20190330626A1 (en) | 2016-07-15 | 2019-10-31 | Ionis Pharmaceuticals, Inc. | Compounds and methods for use in dystrophin transcript |
EP4275747A3 (en) | 2016-07-19 | 2024-01-24 | Duke University | Therapeutic applications of cpf1-based genome editing |
US10933081B2 (en) | 2016-09-21 | 2021-03-02 | Alnylam Pharmaceuticals, Inc. | Myostatin iRNA compositions and methods of use thereof |
JP7060216B2 (ja) | 2016-11-16 | 2022-04-26 | アカデミシュ ジーケンハウス ライデン ハー.オー.デー.エン. ルムク | 多様な選択された臓器又は組織をターゲティングするための物質 |
US10947540B2 (en) | 2016-11-29 | 2021-03-16 | Association Institut De Myologie | Allele-specific silencing therapy for Dynamin 2-related diseases |
CN110382695A (zh) | 2016-11-28 | 2019-10-25 | 得克萨斯州大学系统董事会 | 通过crispr/cpf1介导的基因编辑来预防肌营养不良 |
WO2018107003A1 (en) | 2016-12-08 | 2018-06-14 | The Board Of Regents Of The University Of Texas System | Dmd reporter models containing humanized duschene muscular dystrophy mutations |
JP6956741B2 (ja) | 2016-12-26 | 2021-11-02 | Jcrファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
JOP20190166A1 (ar) | 2017-01-05 | 2019-07-02 | Univ Texas | استراتيجية مثلى من أجل تعديلات تخطي إكسون باستخدام crispr/cas9 مع متواليات توجيه ثلاثي |
SG10202107429WA (en) | 2017-01-06 | 2021-08-30 | Avidity Biosciences Inc | Nucleic acid-polypeptide compositions and methods of inducing exon skipping |
WO2018140831A2 (en) | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
AU2018281280A1 (en) | 2017-06-07 | 2020-01-16 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
US11518995B2 (en) | 2017-09-19 | 2022-12-06 | Children's National Medical Center | Gapmers and methods of using the same for the treatment of muscular dystrophy |
EA201991450A1 (ru) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии |
MA50269A (fr) | 2017-09-22 | 2020-07-29 | Avidity Biosciences Inc | Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon |
JP2020536060A (ja) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | 筋ジストロフィーを処置するための併用療法 |
AU2018345772A1 (en) | 2017-10-02 | 2020-04-23 | Research Institute At Nationwide Children's Hospital | MiRNA detargeting system for tissue specific interference |
CN111655268B (zh) | 2017-10-04 | 2024-03-26 | 艾维迪提生物科学公司 | 核酸-多肽组合物及其用途 |
MA50578A (fr) | 2017-11-09 | 2021-09-15 | Vertex Pharma | Systèmes crispr/cas pour le traitement de dmd |
WO2019110725A1 (en) | 2017-12-06 | 2019-06-13 | Synaffix B.V. | Enediyne conjugates |
CA3083526A1 (en) | 2017-12-06 | 2019-06-13 | Andrew John Geall | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
WO2019136180A2 (en) | 2018-01-04 | 2019-07-11 | Avidity Biosciences Llc | Heteroduplex nucleic acid molecules and uses thereof |
WO2019136216A1 (en) | 2018-01-05 | 2019-07-11 | The Board Of Regents Of The University Of Texas System | Therapeutic crispr/cas9 compositions and methods of use |
JP2021511803A (ja) | 2018-01-31 | 2021-05-13 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ヒト心筋細胞におけるジストロフィン変異を修正するための組成物および方法 |
US20210038653A1 (en) | 2018-02-02 | 2021-02-11 | Fred Hutchinson Cancer Research Center | Methods for treating facioscapulohumeral muscular dystrophy |
MX2020008041A (es) | 2018-02-05 | 2020-09-25 | Japan Chem Res | Metodo para suministrar farmaco al musculo. |
BR112020016005A2 (pt) | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
CA3096667A1 (en) | 2018-04-12 | 2019-10-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
WO2019215175A1 (en) | 2018-05-08 | 2019-11-14 | Roche Innovation Center Copenhagen A/S | Oligonucleotides for modulating myh7 expression |
EP3790968A1 (en) | 2018-05-11 | 2021-03-17 | Alpha Anomeric SAS | Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides |
TW202015726A (zh) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2抗體、組合療法、及使用該等抗體和組合療法之方法 |
US20220251551A1 (en) | 2018-06-13 | 2022-08-11 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
EP3810775A1 (en) | 2018-06-21 | 2021-04-28 | The Board Of Regents Of The University Of Texas System | Correction of dystrophin exon 43, exon 45, or exon 52 deletions in duchenne muscular dystrophy |
US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CN112912399A (zh) | 2018-08-02 | 2021-06-04 | 达因疗法公司 | 肌肉靶向复合物及其用于治疗蓬佩病的用途 |
US20210324101A1 (en) | 2018-08-02 | 2021-10-21 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating hypertrophic cardiomyopathy |
EP3830131A4 (en) | 2018-08-02 | 2023-04-19 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FREDERICH'S ATAXIA |
CA3108282A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CN112930193A (zh) | 2018-08-02 | 2021-06-08 | 达因疗法公司 | 肌肉靶向复合物及其在治疗肌肉萎缩中的用途 |
EP3829649A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETING COMPLEXES AND THEIR USES |
JP2021533199A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 筋強直症ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
EP3830130A4 (en) | 2018-08-02 | 2022-05-18 | Dyne Therapeutics, Inc. | MUSCLE TARGET COMPLEXES AND THEIR USES IN THE TREATMENT OF CENTRONUCLEAR MYOPATHY |
KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
WO2020028831A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating fibrodysplasia ossificans progressiva |
US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
IT201800009682A1 (it) | 2018-10-22 | 2020-04-22 | Ice Spa | Coniugati di acidi biliari e loro derivati per la veicolazione di molecole attive |
CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
CA3123619A1 (en) | 2018-12-21 | 2020-06-25 | Avidity Biosciences, Inc. | Anti-transferrin receptor antibodies and uses thereof |
EP3959319A4 (en) | 2019-04-25 | 2023-06-07 | Avidity Biosciences, Inc. | NUCLEIC ACID COMPOSITIONS AND MULTI-EXON SKIPPING METHODS |
AU2020287880A1 (en) | 2019-06-06 | 2022-01-20 | Avidity Biosciences, Inc. | UNA amidites and uses thereof |
WO2020247782A1 (en) | 2019-06-06 | 2020-12-10 | Avidity Biosciences, Inc. | Nucleic acid-polypeptide compositions and uses thereof |
WO2020247738A1 (en) | 2019-06-07 | 2020-12-10 | Dyne Therapeutics, Inc. | Methods of preparing protein-oligonucleotide complexes |
WO2021003573A1 (en) | 2019-07-09 | 2021-01-14 | The Governors Of The University Of Alberta | Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene |
US20240148891A1 (en) | 2019-10-18 | 2024-05-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
CN115335062A (zh) | 2020-01-10 | 2022-11-11 | 达因疗法公司 | 肌肉靶向复合物及其用于调节与肌肉健康相关的基因的用途 |
WO2021142331A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with cardiac muscle disease |
WO2021142269A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle atrophy |
WO2021142217A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Thereapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of milck1 |
MX2022008533A (es) | 2020-01-10 | 2022-08-08 | Dyne Therapeutics Inc | Complejos dirigidos al musculo y usos de los mismos para el tratamiento de la distrofia miotonica. |
US20230226212A1 (en) | 2020-01-10 | 2023-07-20 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
US20230088865A1 (en) | 2020-01-10 | 2023-03-23 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
BR112022013572A2 (pt) | 2020-01-10 | 2022-09-13 | Dyne Therapeutics Inc | Complexos de direcionamento a músculo e usos dos mesmos para tratar distrofinopatias |
US20230203180A1 (en) | 2020-01-10 | 2023-06-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
WO2021142260A1 (en) | 2020-01-10 | 2021-07-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of acvr1 |
WO2023283531A2 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for modulation of genes associated with muscle health |
WO2021150382A1 (en) | 2020-01-24 | 2021-07-29 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
MX2022009418A (es) | 2020-01-31 | 2022-08-25 | Dyne Therapeutics Inc | Anticuerpo del receptor anti-transferrina (tfr) y usos del mismo. |
WO2021154477A1 (en) | 2020-01-31 | 2021-08-05 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (tfr) antibody and uses thereof |
KR20230046297A (ko) | 2020-07-23 | 2023-04-05 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
JP2023535073A (ja) | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス,インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体およびそれらの使用 |
KR20230041760A (ko) | 2020-07-23 | 2023-03-24 | 다인 세라퓨틱스, 인크. | 항-트랜스페린 수용체 (tfr) 항체 및 그의 용도 |
US20230346966A1 (en) | 2020-07-23 | 2023-11-02 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof in treating muscle atrophy |
AU2021313058A1 (en) | 2020-07-23 | 2023-03-30 | Dyne Therapeutics, Inc. | Muscle-targeting complexes and uses thereof |
JP2023535078A (ja) | 2020-07-23 | 2023-08-15 | ダイン セラピューティクス,インコーポレーテッド | 筋緊張性ジストロフィーを処置するための筋標的化複合体およびその使用 |
AR123420A1 (es) | 2020-09-01 | 2022-11-30 | Ultragenyx Pharmaceutical Inc | Inhibidores de dux4 y métodos de uso de estos |
KR20230079068A (ko) | 2020-09-03 | 2023-06-05 | 다인 세라퓨틱스, 인크. | 단백질-올리고뉴클레오티드 복합체의 제조 방법 |
UY39417A (es) | 2020-09-11 | 2022-03-31 | Arrowhead Pharmaceuticals Inc | Agentes de arni para inhibir la expresión de dux4, composiciones de dichos agentes, y métodos de uso |
JP2023551279A (ja) | 2020-11-30 | 2023-12-07 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 顔面肩甲上腕筋ジストロフィー(fshd)を治療するための組成物及び方法 |
CN116744943A (zh) | 2020-12-04 | 2023-09-12 | 达因疗法公司 | 抗体-寡核苷酸复合物及其用途 |
CA3202832A1 (en) | 2020-12-31 | 2022-07-07 | Romesh R. Subramanian | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
KR20230128314A (ko) | 2020-12-31 | 2023-09-04 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을치료하기 위한 그의 용도 |
EP4281084A1 (en) | 2021-01-22 | 2023-11-29 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing dux4 expression |
CA3222816A1 (en) | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating friedreich's ataxia |
WO2022271549A1 (en) | 2021-06-21 | 2022-12-29 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating pompe disease |
CA3226366A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating dystrophinopathies |
WO2023283629A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations thereof for treating facioscapulohumeral muscular dystrophy |
US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
EP4367143A1 (en) | 2021-07-09 | 2024-05-15 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
AU2022309238A1 (en) | 2021-07-09 | 2024-01-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3226300A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11648318B2 (en) | 2021-07-09 | 2023-05-16 | Dyne Therapeutics, Inc. | Anti-transferrin receptor (TFR) antibody and uses thereof |
US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
WO2023283614A2 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
CA3226365A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
CA3226307A1 (en) | 2021-07-09 | 2023-01-12 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
KR20240058160A (ko) | 2021-09-16 | 2024-05-03 | 다인 세라퓨틱스, 인크. | 디스트로핀병증을 치료하기 위한 근육 표적화 복합체의 투여 |
CN118201640A (zh) | 2021-11-01 | 2024-06-14 | 达因疗法公司 | 用于治疗肌养蛋白病的肌肉靶向复合物 |
IL312170A (en) | 2021-11-12 | 2024-06-01 | Dyne Therapeutics Inc | Muscle targeting complexes for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy |
WO2023201332A1 (en) | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Dosing of muscle targeting complexes for treating myotonic dystrophy |
WO2023201324A1 (en) | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
WO2023201318A1 (en) | 2022-04-15 | 2023-10-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
-
2019
- 2019-08-02 KR KR1020217005993A patent/KR20210081324A/ko unknown
- 2019-08-02 CN CN201980064591.XA patent/CN112912499A/zh active Pending
- 2019-08-02 MX MX2021001284A patent/MX2021001284A/es unknown
- 2019-08-02 WO PCT/US2019/044990 patent/WO2020028864A1/en unknown
- 2019-08-02 US US17/264,948 patent/US20220193250A1/en not_active Abandoned
- 2019-08-02 EP EP19843565.3A patent/EP3830259A4/en active Pending
- 2019-08-02 SG SG11202100928QA patent/SG11202100928QA/en unknown
- 2019-08-02 JP JP2021529261A patent/JP2021533200A/ja active Pending
- 2019-08-02 EA EA202190416A patent/EA202190416A1/ru unknown
- 2019-08-02 AU AU2019316103A patent/AU2019316103A1/en active Pending
- 2019-08-02 CA CA3108289A patent/CA3108289A1/en active Pending
-
2021
- 2021-01-26 IL IL280426A patent/IL280426A/en unknown
- 2021-03-18 US US17/205,123 patent/US11111309B2/en active Active
- 2021-08-12 US US17/400,295 patent/US11286305B2/en active Active
-
2022
- 2022-02-15 US US17/671,707 patent/US11390682B2/en active Active
- 2022-06-22 US US17/846,738 patent/US11518816B2/en active Active
- 2022-09-29 US US17/936,483 patent/US11787869B2/en active Active
-
2023
- 2023-03-16 US US18/184,741 patent/US11795233B2/en active Active
- 2023-03-16 US US18/184,905 patent/US11795234B2/en active Active
- 2023-09-15 US US18/467,851 patent/US12012460B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2020028864A8 (en) | 2020-02-27 |
EA202190416A1 (ru) | 2021-06-23 |
US20230049450A1 (en) | 2023-02-16 |
US20230203181A1 (en) | 2023-06-29 |
US11787869B2 (en) | 2023-10-17 |
US20220193250A1 (en) | 2022-06-23 |
IL280426A (en) | 2021-03-25 |
US12012460B2 (en) | 2024-06-18 |
US11795233B2 (en) | 2023-10-24 |
US20240067743A1 (en) | 2024-02-29 |
WO2020028864A1 (en) | 2020-02-06 |
EP3830259A1 (en) | 2021-06-09 |
US11286305B2 (en) | 2022-03-29 |
MX2021001284A (es) | 2021-07-15 |
CA3108289A1 (en) | 2020-02-06 |
US20220169743A1 (en) | 2022-06-02 |
US20230227569A1 (en) | 2023-07-20 |
KR20210081324A (ko) | 2021-07-01 |
AU2019316103A1 (en) | 2021-03-11 |
US20210380709A1 (en) | 2021-12-09 |
JP2021533200A (ja) | 2021-12-02 |
US11518816B2 (en) | 2022-12-06 |
CN112912499A (zh) | 2021-06-04 |
US11795234B2 (en) | 2023-10-24 |
US11111309B2 (en) | 2021-09-07 |
EP3830259A4 (en) | 2022-05-04 |
US20220324992A1 (en) | 2022-10-13 |
US20210206868A1 (en) | 2021-07-08 |
US11390682B2 (en) | 2022-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL280426A (en) | Muscle oriented compositions and their uses for the treatment of facial, shoulder and arm muscle atrophy | |
IL280425A (en) | Muscle directed couplings and their uses in the treatment of dystrophic myotonia | |
IL280536A (en) | Muscle oriented clasps and their uses | |
IL280527A (en) | Muscle-directed couplings and their use in the treatment of dystrophinopathy | |
IL299666A (en) | Muscle targeting complexes and their uses for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
IL280483A (en) | Muscle targeting complexes and uses thereof for treating pompe disease | |
EP4045060A4 (en) | MUSCLE TARGETED COMPLEXES AND THEIR USES FOR TREATING MYOTONIC DYSTROPHY | |
EP3829594A4 (en) | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY | |
EP3830130A4 (en) | MUSCLE TARGET COMPLEXES AND THEIR USES IN THE TREATMENT OF CENTRONUCLEAR MYOPATHY | |
IL280535A (en) | Muscle-directed couplings and their uses in the treatment of Friedreich's ataxia | |
SG11202105873SA (en) | Combination therapy for treating muscular dystrophy | |
IL312170A (en) | Muscle targeting complexes for the treatment of FACIOSCAPULOHUMERAL muscular dystrophy | |
IL280526A (en) | Bracelets targeting the muscle and their use for the treatment of muscle atrophy | |
IL299663A (en) | Muscle targeting complexes and their uses for the treatment of myotonic dystrophy | |
SG11202104356VA (en) | Bt1718 for use in treating cancer | |
PH12016500270A1 (en) | Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases | |
GB201903546D0 (en) | Cancer treatment | |
EP3746082A4 (en) | METHOD OF TREATMENT OF FACIOUS CAPULOHUMERAL MUSCULAR DYSTROPHY | |
ZA201804361B (en) | 1,3,4-thiadiazole compounds and their use in treating cancer | |
IL259510A (en) | 1, 3, 4-thiadiazole compounds and their use for cancer treatment | |
EP3535588A4 (en) | THERAPEUTIC TARGET MOLECULES FOR FACIO-CAPULOHUMERAL MUSCLE DYSTROPHY | |
TW201713323A (en) | Therapeutic compositions and methods of use thereof | |
IL285466A (en) | Cancer treatment | |
SG11202108757XA (en) | Methods for treating muscular dystrophy with casimersen | |
IL269121A (en) | Usl-311 for use in the treatment of cancer |